Zydus Cadila receives tentative approval from USFDA for Lacosamide Tablets

08 Apr 2019 Evaluate

Zydus Cadila has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Lacosamide Tablets (US RLD -Vimpat) in the strengths of 50 mg, 100 mg, 150 mg and 200 mg. Lacosamide is an anticonvulsant or antiepileptic drug, used to prevent and control seizures. It works by reducing the spread of seizure activity in the brain. The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad in the state of Gujarat.

The group now has 261 approvals and has so far filed over 350 ANDA’s since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

920.00 6.10 (0.67%)
17-Dec-2025 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.45
Dr. Reddys Lab 1273.40
Cipla 1498.50
Zydus Lifesciences 920.00
Lupin 2118.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×